Search
‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda
On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.
Read moreHighlights of Past EHA (HOPE ) Asia 2021 - report
In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.
Read moreMessage from the EHA Board
After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.
Read moreHelping steer EHA into the future
In 2020, EHA launched the Taskforce on Diversity, Equity, and Inclusion with an EHA Board mandate.
Read moreGoCART Coalition - Call for research proposals within Work Package 6: Scientific Excellence
Dear GoCART community,
With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific Excellence of the GoCART coalition.
EHA-EBMT 3rd European CAR T-cell Meeting (Virtual)
Dates: February 4-6, 2021
Chairs: H Einsele (EHA) & C Chabannon (EBMT)
For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…
Celebrating the International Day of Women & Girls in Science
On this International Day of Women & Girls in Science, we take a moment to honor, appreciate and thank, all the women scientists at the forefront of the fight against COVID-19.
Read moreT2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
Report VIRTUAL EHA-SWG Scientific Meeting on Immunotherapy
This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.
Read moreEHA has joined the European Cancer Organisation - a perfect match on objectives and prioritization
The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level.
Read more